Compare · IRON vs NVS
IRON vs NVS
Side-by-side comparison of Disc Medicine Inc. (IRON) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRON and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 100.9x IRON ($2.91B).
- Over the past year, IRON is up 28.1% and NVS is up 34.7% - NVS leads by 6.6 points.
- IRON has hit the wire 6 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 20 for IRON).
- Company
- Disc Medicine Inc.
- Novartis AG
- Price
- $76.19+3.84%
- $153.72+0.64%
- Market cap
- $2.91B
- $293.40B
- 1M return
- +9.11%
- +1.89%
- 1Y return
- +28.05%
- +34.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 20
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest IRON
- Chief Executive Officer Quisel John D exercised 33,000 shares at a strike of $10.68 and sold $2,473,780 worth of shares (33,000 units at $74.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Disc Medicine Inc.
- Chief Operating Officer Yu Jonathan Yen-Wen exercised 100 shares at a strike of $13.50 and sold $8,250 worth of shares (100 units at $82.50) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Legal Officer Khara Rahul exercised 2,500 shares at a strike of $14.69 and sold $187,500 worth of shares (2,500 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Yu Jonathan Yen-Wen sold $21,750 worth of shares (300 units at $72.50) as part of a pre-agreed trading plan and exercised 300 shares at a strike of $13.50 (SEC Form 4)
- Disc Medicine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Chief Operating Officer Yu Jonathan Yen-Wen exercised 9,700 shares at a strike of $13.50 and sold $704,795 worth of shares (9,700 units at $72.66) as part of a pre-agreed trading plan (SEC Form 4)
- Disc Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Legal Officer Khara Rahul exercised 7,500 shares at a strike of $14.69 and sold $526,661 worth of shares (7,500 units at $70.22) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Quisel John D exercised 34,000 shares at a strike of $9.86 and sold $2,387,296 worth of shares (34,000 units at $70.21) as part of a pre-agreed trading plan (SEC Form 4)
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG